Edema Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Phase (Phase I, Phase II, Phase III, Phase IV), By Participants (Pediatrics, Adults, Geriatrics), By Sponsor (Pharmaceutical Companies, Academic Institutions, Government Bodies), By Type (Systemic Edema, Localized Edema), By Region and Competition, 2020-2030F

December 2025 | 185 pages | ID: E824527017EBEN
TechSci Research

Abstracts

The Global Edema Clinical Trials Market, valued at USD 1.19 Billion in 2024, is projected to experience a CAGR of 4.00% to reach USD 1.51 Billion by 2030. The Global Edema Clinical Trials Market focuses on research studies evaluating the safety and efficacy of novel drugs, therapies, and medical devices developed to manage edema, which involves the abnormal accumulation of fluid in body tissues.

Key Market Drivers

The rising global burden of edema-associated chronic diseases is a primary impetus for the clinical trials market. As the prevalence of conditions like heart failure, kidney disease, and liver cirrhosis escalates, the concurrent incidence of edema increases significantly. This expanding patient demographic urgently requires advanced therapeutic interventions. According to the World Health Organization (WHO), in a fact sheet updated May 2023, noncommunicable diseases (NCDs) accounted for 41 million deaths annually in 2021, representing 74% of all global deaths, with many NCDs directly contributing to edema.

Key Market Challenges

The considerable financial investment required for conducting comprehensive clinical trials, coupled with extended timelines for regulatory approvals, presents a substantial impediment to the growth of the Global Edema Clinical Trials Market. The extensive capital outlay necessary for drug development, encompassing preclinical research through all phases of human trials, acts as a significant barrier for pharmaceutical companies.

Key Market Trends

The increased use of biomarkers for personalized treatment is a significant trend in edema clinical trials. This approach enhances drug development by identifying specific patient subpopulations likely to respond to a therapy, thereby improving trial efficiency and therapeutic outcomes. For example, in April 2025, research identified choroidal thickness (CCT) as a crucial biomarker for diabetic macular edema, where normal CCTs correlated with better treatment responses to aflibercept.

Key Market Players

• Otsuka Holdings Co. Ltd.
• Novartis AG
• Genentech, Inc.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Sanofi S.A.
• AstraZeneca plc
• Bristol Myers Squibb India Pvt. Ltd.
• GlaxoSmithKline plc
• AbbVie Inc.

Report Scope:

In this report, the Global Edema Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Edema Clinical Trials Market, By Phase:
• Phase I
• Phase II
• Phase III
• Phase IV
• Edema Clinical Trials Market, By Participants:
• Pediatrics
• Adults
• Geriatrics
• Edema Clinical Trials Market, By Sponsor:
• Pharmaceutical Companies
• Academic Institutions
• Government Bodies
• Edema Clinical Trials Market, By Type:
• Systemic Edema
• Localized Edema
• Edema Clinical Trials Market, By Region:
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Edema Clinical Trials Market.

Available Customizations:

Global Edema Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL EDEMA CLINICAL TRIALS MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Phase (Phase I, Phase II, Phase III, Phase IV)
  5.2.2. By Participants (Pediatrics, Adults, Geriatrics)
  5.2.3. By Sponsor (Pharmaceutical Companies, Academic Institutions, Government Bodies)
  5.2.4. By Type (Systemic Edema, Localized Edema)
  5.2.5. By Region
  5.2.6. By Company (2024)
5.3. Market Map

6. NORTH AMERICA EDEMA CLINICAL TRIALS MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Phase
  6.2.2. By Participants
  6.2.3. By Sponsor
  6.2.4. By Type
  6.2.5. By Country
6.3. North America: Country Analysis
  6.3.1. United States Edema Clinical Trials Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Phase
      6.3.1.2.2. By Participants
      6.3.1.2.3. By Sponsor
      6.3.1.2.4. By Type
  6.3.2. Canada Edema Clinical Trials Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Phase
      6.3.2.2.2. By Participants
      6.3.2.2.3. By Sponsor
      6.3.2.2.4. By Type
  6.3.3. Mexico Edema Clinical Trials Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Phase
      6.3.3.2.2. By Participants
      6.3.3.2.3. By Sponsor
      6.3.3.2.4. By Type

7. EUROPE EDEMA CLINICAL TRIALS MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Phase
  7.2.2. By Participants
  7.2.3. By Sponsor
  7.2.4. By Type
  7.2.5. By Country
7.3. Europe: Country Analysis
  7.3.1. Germany Edema Clinical Trials Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Phase
      7.3.1.2.2. By Participants
      7.3.1.2.3. By Sponsor
      7.3.1.2.4. By Type
  7.3.2. France Edema Clinical Trials Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Phase
      7.3.2.2.2. By Participants
      7.3.2.2.3. By Sponsor
      7.3.2.2.4. By Type
  7.3.3. United Kingdom Edema Clinical Trials Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Phase
      7.3.3.2.2. By Participants
      7.3.3.2.3. By Sponsor
      7.3.3.2.4. By Type
  7.3.4. Italy Edema Clinical Trials Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Phase
      7.3.4.2.2. By Participants
      7.3.4.2.3. By Sponsor
      7.3.4.2.4. By Type
  7.3.5. Spain Edema Clinical Trials Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Phase
      7.3.5.2.2. By Participants
      7.3.5.2.3. By Sponsor
      7.3.5.2.4. By Type

8. ASIA PACIFIC EDEMA CLINICAL TRIALS MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Phase
  8.2.2. By Participants
  8.2.3. By Sponsor
  8.2.4. By Type
  8.2.5. By Country
8.3. Asia Pacific: Country Analysis
  8.3.1. China Edema Clinical Trials Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Phase
      8.3.1.2.2. By Participants
      8.3.1.2.3. By Sponsor
      8.3.1.2.4. By Type
  8.3.2. India Edema Clinical Trials Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Phase
      8.3.2.2.2. By Participants
      8.3.2.2.3. By Sponsor
      8.3.2.2.4. By Type
  8.3.3. Japan Edema Clinical Trials Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Phase
      8.3.3.2.2. By Participants
      8.3.3.2.3. By Sponsor
      8.3.3.2.4. By Type
  8.3.4. South Korea Edema Clinical Trials Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Phase
      8.3.4.2.2. By Participants
      8.3.4.2.3. By Sponsor
      8.3.4.2.4. By Type
  8.3.5. Australia Edema Clinical Trials Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Phase
      8.3.5.2.2. By Participants
      8.3.5.2.3. By Sponsor
      8.3.5.2.4. By Type

9. MIDDLE EAST & AFRICA EDEMA CLINICAL TRIALS MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Phase
  9.2.2. By Participants
  9.2.3. By Sponsor
  9.2.4. By Type
  9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
  9.3.1. Saudi Arabia Edema Clinical Trials Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Phase
      9.3.1.2.2. By Participants
      9.3.1.2.3. By Sponsor
      9.3.1.2.4. By Type
  9.3.2. UAE Edema Clinical Trials Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Phase
      9.3.2.2.2. By Participants
      9.3.2.2.3. By Sponsor
      9.3.2.2.4. By Type
  9.3.3. South Africa Edema Clinical Trials Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Phase
      9.3.3.2.2. By Participants
      9.3.3.2.3. By Sponsor
      9.3.3.2.4. By Type

10. SOUTH AMERICA EDEMA CLINICAL TRIALS MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Phase
  10.2.2. By Participants
  10.2.3. By Sponsor
  10.2.4. By Type
  10.2.5. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil Edema Clinical Trials Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Phase
      10.3.1.2.2. By Participants
      10.3.1.2.3. By Sponsor
      10.3.1.2.4. By Type
  10.3.2. Colombia Edema Clinical Trials Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Phase
      10.3.2.2.2. By Participants
      10.3.2.2.3. By Sponsor
      10.3.2.2.4. By Type
  10.3.3. Argentina Edema Clinical Trials Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Phase
      10.3.3.2.2. By Participants
      10.3.3.2.3. By Sponsor
      10.3.3.2.4. By Type

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. GLOBAL EDEMA CLINICAL TRIALS MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

15.1. Otsuka Holdings Co. Ltd.
  15.1.1. Business Overview
  15.1.2. Products & Services
  15.1.3. Recent Developments
  15.1.4. Key Personnel
  15.1.5. SWOT Analysis
15.2. Novartis AG
15.3. Genentech, Inc.
15.4. Johnson & Johnson Services, Inc.
15.5. Merck & Co., Inc.
15.6. Sanofi S.A.
15.7. AstraZeneca plc
15.8. Bristol Myers Squibb India Pvt. Ltd.
15.9. GlaxoSmithKline plc
15.10. AbbVie Inc.

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER